

Please amend the specification as described below. As required by 37 C.F.R. § 1.121(b)(1), the amended paragraph is rewritten with all changes included. In addition, also attached, is a marked-up version of the amended paragraph, marked to show all of the changes relative to the previous version.

**On page 49, please delete the paragraph at lines 19-29 and replace it with the following paragraph:**

The DNA from 4 µg of AMV reverse transcription and 2.0 µg of Moloney MLV reverse transcription were combined. Non-selfcomplementary BstXI adaptors were added to the DNA as follows: The double-stranded cDNA from 6 µg of poly(A)+ RNA was incubated with 3.6 µg of a kinased oligonucleotide of the sequence CTTTAGAGCACA (SEQ ID NO:9) and 2.4 µg of a kinased oligonucleotide of the sequence CTCTAAAG (SEQ ID NO:14) in a solution containing 6 mM Tris, pH 7.5, 6 mM MgCl<sub>2</sub>, 5 mM NaCl, 350 µg/ml bovine serum albumin, 7 mM mercaptoethanol, 0.1 mM ATP, 2 mM dithiothreitol, 1mM spermidine, and 600 units T4 DNA ligase in a total volume of 0.45 ml at 15° C for 16 hours. EDTA was added to 34 mM and the solution was extracted with an equal volume of 50 % phenol, 49 % chloroform, 1 % isoamyl alcohol. DNA was precipitated with two volumes of ethanol in the presence of 2.5 M ammonium acetate.

**Remarks**

In accordance with the provisions of f 37 C.F.R. §§ 1.821-1.825, Applicants have amended the specification to insert the written copy of the Sequence Listing. A copy of the Sequence Listing in computer readable form, the contents of which are identical to the written form of the Sequence Listing, is also enclosed.

This amendment does not introduce new subject matter as support is found in the Application as filed.